Beyond Single-Agent Approaches : Vast Compounded Sublingual Formulation for Erectile Wellness

Perspective on a Multi-Pathway Option for Erectile Wellness  Beyond Single-Agent Approaches 

Chemistry-Fueled Support. Vast represents a multi-layered approach to erectile wellness, bringing together complementary pathways in a single compounded formulation designed to support erectile response.

Erectile dysfunction (ED) management commonly begins with phosphodiesterase type 5 (PDE5) inhibitor monotherapy.¹ While many patients respond, some experience inconsistent or limited response to a single agent.¹

In these cases, providers may consider formulations that address more than one contributing pathway. Vast is a compounded, on-demand, sublingual formulation designed to engage both vascular and neurochemical pathways involved in sexual arousal and erectile response.^1,2

Escalation Strategies: Considerations for Patients with Prior PDE5 Experience

Vast is positioned for patients who have already trialed PDE5 inhibitor monotherapy, such as sildenafil, tadalafil, or vardenafil, and have not achieved consistent or satisfactory response .^3,4

Vast may be considered when monotherapy alone has not been sufficient. This positioning reflects the clinical reality that erectile concerns may involve overlapping psychogenic, neurogenic, and vascular contributors that may not be addressed by a single pharmacologic pathway alone.⁵

For providers seeking additional options when traditional approaches fall short, Vast introduces a multi-mechanistic strategy for supporting erectile response.

The Vast Formulation: Multi-Pathway Support

VAST combines three ingredients to target erectile challenges from multiple angles. The compounded formulation contains:

• Apomorphine 3 mg
  
  
• Tadalafil 20 mg
  
  
• Vardenafil 15 mg
  
  

Each component contributes to supporting erectile response through distinct pathways, creating a multi-layered approach to erectile wellness.^6,7,8  

Apomorphine: Central Arousal Signaling

Apomorphine is a centrally acting dopamine D1/D2 receptor agonist discussed in relation to stimulation of sexual arousal through hypothalamic and limbic pathways.² Its activity is largely independent of nitric oxide signaling.

With rapid absorption and a relatively short half-life, apomorphine is often discussed in relation to initiation of the arousal–erection sequence. This central mechanism may be particularly helpful in individuals whose erectile challenges may include psychogenic or neurogenic components.²

Tadalafil and Vardenafil: Peripheral Blood Flow Support

Tadalafil and vardenafil belong to the PDE5 inhibitor class and work by limiting the breakdown of cyclic guanosine monophosphate (cGMP), which supports vasodilation in penile tissue.¹

Although they share a mechanism of action, their pharmacologic profiles differ:

• Tadalafil is distinguished by a longer half-life, which may provide an extended window of responsiveness.⁷
  
  
• Vardenafil has a shorter duration of action and has been discussed in relation to individualized response.⁸
  
  

Together, tadalafil and vardenafil support the peripheral blood-flow component of erectile function.^1,7,8

‍

Multi-Mechanistic Support: Central Arousal and Peripheral Vasodilation

Vast may bring together:

• Peripheral vasodilation through PDE5 inhibition
  
  
• Central dopaminergic signaling related to arousal
  
  

This multi-pathway approach aligns with clinical observations that erectile wellness  may involve both vascular and central nervous system contributors.^1,2

By engaging complementary pathways, Vast can be a supportive option for individuals who may not have experienced desired outcomes with single-agent PDE5 regimen.

‍

Potential Benefits

When prescribed and monitored by a healthcare provider, Vast may offer potential benefits such as:

• May support erection firmness and duration^1,7,8
  
  
• May support healthy libido, arousal levels, and sexual readiness ²
  
  
• May support responsiveness to sexual stimulation^7,8
  
  
• Addresses both peripheral (blood flow) and central (dopaminergic arousal) mechanisms^1,2
  
  

Individual responses may vary based on underlying health conditions, contributing factors to erectile wellness, and overall patient context.

‍

Sublingual Administration: Flexible Timing Around Intimacy

Vast is compounded as a mint-flavored sublingual tablet, offering an alternative delivery method designed for individualized dosing.

Sublingual delivery offers flexible timing around intimacy while supporting rapid absorption though individual pharmacokinetic response may vary.

Suggested administration guidance includes:

• Dissolve ½ to 1 tablet sublingually or buccally
  
  
• Take approximately 30–60 minutes prior to anticipated sexual activity^7,8
  
  
• Use is on-demand only and should not exceed one dose within a 48-hour period
  
  

This flexible approach allows providers to tailor dosing based on patient response and tolerability.

Prescribing Considerations and Clinical Caution

Given the inclusion of multiple vasodilatory agents, providers are advised to evaluate patient suitability carefully.

Clinical considerations may include:

• Cardiovascular history¹
  
  
• Baseline blood pressure¹
  
  
• Concomitant antihypertensive medications¹
  
  
• Sensitivity to dopaminergic stimulation²
  
  

Vast is not intended for daily use and is positioned strictly as an on-demand option.

Contraindications include:

• Use of nitrate medications¹
  
  
• Unstable cardiovascular disease¹
  
  
• Baseline hypotension¹
  
  

These considerations reinforce the importance of prescribing oversight and individualized patient evaluation.

‍

Possible Side Effects

Based on referenced literature and clinical context, possible side effects may include:

• Headache^7,8
  
  
• Flushing^7,8
  
  
• Nasal congestion^7,8
  
  
• Dizziness or lightheadedness^7,8
  
  
• Nausea (more commonly associated with apomorphine)²
  
  
• Blood pressure fluctuations¹
  
  

Rare but serious side effects such as Priapism may occur. If an erection lasts longer than 4 hours seek immediate medical attention.¹ These considerations highlight the importance of provider counseling and monitoring.

‍

Summary: When Vast May Be Considered in Erectile Wellness 

Vast reflects a compounded option for individuals with mixed or inconsistent response to PDE5 inhibitor monotherapy.

For providers seeking a multi-layered approach to erectile management, Vast may be considered when prior options  have not produced consistent outcomes and when provider judgment supports a multi-mechanistic, on-demand strategy.^3,4

It’s a vast new frontier for erectile challenges, with a compounded option designed to support erectile response through multiple complementary pathways.

‍

Partnering With Strive Pharmacy

Strive Pharmacy partners with prescribing providers to support individualized compounded formulations, flexible dosing, and pharmacist access.

Explore a vast new frontier of possibilities for erectile wellness.

Providers interested in Vast are welcome to connect with Strive’s clinical liaison team to discuss whether this option aligns with patient-specific considerations.

‍

‍

^{This information is for educational and informational purposes only and is not a treatment recommendation. The information provided relates to patient-specific medications. Compounded medications are specially prepared for individual patient needs and, as such, have not been reviewed or approved by the U.S. Food and Drug Administration (FDA). The above statements have not been evaluated by the FDA. Prescribers should use their independent clinical judgment when determining appropriateness for individual patients.}

‍

References 

‍

1. Dhaliwal A, Gupta M. PDE5 inhibitors. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; updated April 10, 2023. Accessed January 2025.
2. Melis MR, Sanna F, Argiolas A. Dopamine, erectile function and male sexual behavior from the past to the present: a review. Brain Sci. 2022;12(7):826. doi:10.3390/brainsci12070826. PMID:35884633. PMCID:PMC9312911.
3. Hua V, Roth B, Shumaker A, Bole R, Bajic P. What are options for my patients with erectile dysfunction who have an unsatisfactory response to PDE5 inhibitors? Cleveland Clinic Journal of Medicine. 2024;91(11):667-670. doi:10.3949/ccjm.91a.24005
4. Pyrgidis N, Mykoniatis I, Haidich AB, et al. Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. BMJ Open. 2021;11(8):e047396. doi:10.1136/bmjopen-2020-047396. 
5. Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. 1996;54(5):1675-1682. PMID: 8857789.
6. Mulhall JP. Sublingual apomorphine for the treatment of erectile dysfunction. Expert Opin Investig Drugs. 2002;11(2):295-302. doi:10.1517/13543784.11.2.295. PMID: 11829718.
7. Fahmy G, Hess J. Tadalafil. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; updated March 20, 2024. Accessed January 2025. 
8. Montorsi F, Hellstrom WJ, Valiquette L, et al; North American and European Vardenafil Groups. Vardenafil provides reliable efficacy over time in men with erectile dysfunction. Urology. 2004;64(6):1187-1195. doi:10.1016/j.urology.2004.07.032. PMID:15596195.

‍